Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Last trade$105.24
Day change-$2.21 (-2.06%)
Day range$105.02 – $108.24
Volume2,663,568
Market cap$186.10B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$186.1B
Price / earnings
39.59×
Price / book
3.65×
Price / sales
3.86×
EV / sales
4.42×
EV / EBITDA
20.19×
Profitability
Earnings per share
$2.71
Return on assets
4.34%
Return on equity
9.21%
Dividend yield
2.32%
Liquidity and leverage
Debt / equity
0.61×
Current ratio
1.45×
Quick ratio
1×
Cash ratio
0.25×
Cash flow
Price / cash flow
21.02×
Price / free cash flow
27.54×
Free cash flow
$6.76B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ABT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$13.01B
$12.59B
$11.16B
$11.46B
$11.37B
$11.14B
$10.36B
$10.97B
Cost of revenue
$5.63B
$5.33B
$4.89B
$4.92B
$5.08B
$4.85B
$4.47B
$4.94B
Gross profit
$7.39B
$7.27B
$6.27B
$6.54B
$6.29B
$6.29B
$5.89B
$6.03B
Selling, general and administrative
$4.27B
$4.03B
$3.74B
$3.13B
$3.05B
$3.09B
$3.06B
$2.91B
Research and development
$920M
$892M
$767M
$735M
$766M
$725M
$716M
$749M
Total operating expenses
$6.03B
$5.58B
$4.93B
$4.29B
$4.24B
$4.24B
$4.2B
$4.12B
Operating income
$1.36B
$1.69B
$1.35B
$2.25B
$2.06B
$2.05B
$1.69B
$1.91B
Interest expense
-$350M
-$351M
-$174M
-$120M
-$121M
-$121M
-$131M
-$136M
Income before taxes
$1.23B
$1.52B
$1.45B
$2.36B
$2.18B
$2.15B
$1.78B
$2.03B
Income taxes
$311M
$596M
$372M
$582M
$536M
$371M
$453M
-$7.2B
Net income
$920M
$928M
$1.08B
$1.78B
$1.64B
$1.78B
$1.33B
$9.23B
Net income attributable to common shareholders
$920M
$928M
$1.08B
$1.78B
$1.64B
$1.78B
$1.33B
$9.23B
EBITDA
$2.61B
$2.75B
$2.15B
$3.04B
$2.85B
$2.83B
$2.45B
$2.72B
Basic earnings per share
$0.53
$0.53
$0.62
$1.00
$0.94
$1.02
$0.76
$5.22
Diluted earnings per share
$0.53
$0.53
$0.61
$1.03
$0.94
$1.01
$0.76
$5.39
Recent news
Company coverage with links to the original publishers.
The global nerve repair and regeneration market is projected to grow from USD 10.65 billion in 2025 to USD 20.97 billion by 2031, expanding at an 11.96% CAGR. Growth is driven by rising nerve injuries, advances in neurostimulation technologies, and biomaterial innovations. Neurostimulation devices currently dominate with 58.74% market share, while biomaterials are the fastest-growing segment at 14.01% CAGR. High implant costs and cybersecurity risks remain challenges, with Asia-Pacific expected to record the fastest regional growth.
Abbott reported strong mid-to-high-teens EP sales growth globally and over 20% in the U.S., driven by accelerating Volt PFA catheter adoption following its August launch. The company received FDA approval for TactiFlex Duo and CE Mark for Amulet 360, expanding treatment options. However, LAA market weakness is creating headwinds as customers delay purchases awaiting the new Amulet 360 device. Abbott expects Japan's Q4 Volt launch to provide growth momentum.
Pfizer and AbbVie offer different appeals for income investors. Pfizer boasts a high 5.9% dividend yield with a manageable 89% free cash flow payout ratio, though it faces a patent cliff. AbbVie, a Dividend King with 53 consecutive years of dividend increases, offers lower yield (2.35%) but stronger growth prospects and has successfully navigated its own patent cliff with strong new products like Skyrizi and Rinvoq.
Abbott reported Q3 2026 sales growth of 14.5% to $13.01 billion with broad-based strength across Established Pharmaceuticals, Medical Devices, and Diagnostics segments. The company announced plans to separate its Nutrition business into an independent publicly traded company by end of 2027. However, Abbott narrowed its 2026 sales growth guidance to 6% from 6.5-7.5% due to headwinds in Electrophysiology and Diabetes Care segments. The stock has outperformed peers and sector benchmarks over the past six months but is rated a Hold.
Boston Scientific's WATCHMAN left atrial appendage closure device continues to face declining demand despite positive clinical trial results and expansion efforts. The company expects low-single-digit sequential sales declines in Q3 2026 and assumes no market improvement in 2027, while competitors like Abbott and Edwards Lifesciences show stronger momentum in electrophysiology and structural heart segments.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Oct 15, 2026
$0.63
Nov 16, 2026
recurring
Jul 15, 2026
$0.63
Aug 17, 2026
recurring
Apr 15, 2026
$0.63
May 15, 2026
recurring
Jan 15, 2026
$0.63
Feb 13, 2026
recurring
Oct 15, 2025
$0.59
Nov 17, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.